Loading
CAR-T Cell Therapy Research / Esophageal Cancer Research and Treatment · Journal article
Journal of Clinical Oncology · August 17, 2026
A consensus or society position rather than new primary data.
This is an ASCO Living Guideline on immunotherapy and targeted therapy for advanced gastroesophageal cancer, version 2026.1.2, updated on an eight-week cycle by systematic expert review. The guideline reflects current evidence but is not a primary research study and does not substitute for individual clinical judgment.
Clinical Practice Guideline with systematic literature review. Patients with advanced gastroesophageal cancer.
This is an ASCO Living Guideline on immunotherapy and targeted therapy for advanced gastroesophageal cancer, version 2026.1.2, updated on an eight-week cycle by systematic expert review. The guideline reflects current evidence but is not a primary research study and does not substitute for individual clinical judgment.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should consult the full guideline document and its online dynamic version for specific treatment recommendations. The guideline is updated regularly; the provided text does not specify individual recommendations or evidence grades.
This is an ASCO clinical practice guideline using systematic evidence review for immunotherapy and targeted therapy in advanced gastroesophageal cancer, updated on a regular cycle to reflect evolving evidence.
As stated by the source record.
Clinicians should consult the full guideline document and its online dynamic version for specific treatment recommendations. The guideline is updated regularly; the provided text does not specify individual recommendations or evidence grades.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings, reported figures. That is a gap in the analysis, not a judgement about the study.
This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix I and Appendix II). Updates are published regularly and can be found on the ASCO Publications website.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.